Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Ribociclib + Fulvestrant: Preserving Quality of Life

Strategic Analysis of MONALEESA-3 Patient-Reported Outcomes
0.81
Hazard Ratio (GHS Deterioration)
vs Placebo (Lower is Better)
35.9 mo
Median Time to Deterioration
Ribociclib Arm (+2.8 mo vs Placebo)
0.77
Hazard Ratio (Pain Severity)
Significant Risk Reduction
N=726
Total Population
Randomized 2:1

Study Design & Population

MONALEESA-3 Structure

Delaying Deterioration: Hazard Ratios

HR < 1.0 favors Ribociclib
Ribociclib consistently reduces the risk of definitive deterioration across key Quality of Life domains compared to placebo.

Extending Time to Deterioration

Median Months (Global Health Status)

Baseline Comparability

EORTC QLQ-C30 Scores (0-100)
Groups were well-balanced at study entry. Differences in outcomes are attributable to treatment effect.

Pain Management Efficacy

Risk Reduction in Pain Severity

Functional Domains

Physical vs Emotional Functioning (HR)
"In addition to significantly prolonging PFS and OS compared with placebo plus fulvestrant, adding ribociclib to fulvestrant maintains HRQOL."

Data Appendix

Metric Group Value Source
Source:
DOI:
Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode